Time & Date: 2 September, 16:30 – 17:30 CEST
Chairpersons: R. Tadayoni FRANCE, J. García Arumí SPAIN & K. Resaei USA
Speakers & Presentations:
R. Tadayoni FRANCE
16:30 Introduction
A. Loewenstein ISRAEL
16:31 Interim results from a global survey to better understand the management of diabetic macular edema and diabetic retinopathy from the perspectives of patients, physicians, and clinic staff
16:36 Discussion
A. Khanani USA
16:38 BEHOLD Trial 12-week Data: Phase 2 Study of UBX1325, A Novel Senolytic Agent Being Studied for Patients with Advanced DME
16:43 Discussion
A. Khanani USA
16:45 KSI-301 Anti-VEGF Antibody Biopolymer Conjugate for Retinal Vein Occlusion: Primary 24-Week Efficacy and Safety Outcomes of the BEACON Phase III Pivotal Study
16:50 Discussion
Q. Li USA
15:52 The first clinical results at 12 months post intravitreal administration of NFS-02 (rAAV2-ND1) for the gene therapy treatment of Leber’s Hereditary Optic Neuropathy with ND1 G3460A mutation.
16:57 Discussion
F.G. Holz GERMANY
16:59 OAKS and DERBY Phase 3 trials: analyses of pegcetacoplan efficacy in GA due to AMD at 18 months using three different statistical models
17:04 Discussion
P. Kertes CANADA
17:06 Thirty-two-week results from TALON, a Phase IIIb study of brolucizumab versus aflibercept in a matched (Treat-and-Extend) regimen in patients with neovascular age-related macular degeneration
17:11 Discussion
V. Sheth USA
17:13 Real World Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study
17:18 Discussion
A. Sharma INDIA
(presented by R. Tadayoni)
17:20 Biosimilars for Retinal Diseases- United States-Europe Awareness Survey (Bio-USER –Survey)
17:25 Discussion
R. Tadayoni FRANCE
17:27 Closing Remarks
